Zoetis (ZTS) Stock Forecast & Price Target

$164.84 +1.32 (+0.81%)

(As of 12/20/2024 05:31 PM ET)

Zoetis - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 11 Analyst Ratings

Sell
0

Hold
1

Buy
10

Based on 11 Wall Street analysts who have issued ratings for Zoetis in the last 12 months, the stock has a consensus rating of "Buy." Out of the 11 analysts, 1 has given a hold rating, 8 have given a buy rating, and 2 have given a strong buy rating for ZTS.

Consensus Price Target

$215.22
30.56% Upside

According to the 11 analysts' twelve-month price targets for Zoetis, the average price target is $215.22. The highest price target for ZTS is $230.00, while the lowest price target for ZTS is $196.00. The average price target represents a forecasted upside of 30.56% from the current price of $164.84.

Get the Latest News and Ratings for ZTS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Zoetis and its competitors.

ZTS Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	2 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	9 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)
Hold	1 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$215.22	$221.44	$220.38	$220.11
Forecasted Upside	30.56% Upside	25.12% Upside	13.84% Upside	12.89% Upside
Consensus Rating	Buy	Buy	Buy	Buy

Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)

I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.

Click here to see the details because I believe a lot of people will get rich.

ZTS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ZTS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Zoetis Stock vs. The Competition

Type	Zoetis	Medical Companies	S&P 500
Consensus Rating Score	3.09	2.81	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	30.56% Upside	25,827.32% Upside	14.53% Upside
News Sentiment Rating	Neutral News See Recent ZTS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/9/2024	UBS Group 4 of 5 stars		Initiated Coverage	Neutral	$196.00	+10.04%
12/2/2024	Leerink Partnrs 5 of 5 stars	D. Clark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
12/2/2024	Leerink Partners 1 of 5 stars		Initiated Coverage	Outperform	$215.00	+22.68%
10/11/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$225.00 ➝ $230.00	+20.70%
9/18/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$200.00 ➝ $210.00	+7.29%
8/14/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$195.00 ➝ $210.00	+14.14%
How to piss off your liberal friends… and profit from it (Ad) Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies. To get the full details on the fake “energy crisis” of America, watch this now
8/12/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Massaro Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$220.00 ➝ $225.00	+22.75%
8/9/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Hellweg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$230.00 ➝ $225.00	+36.80%
5/6/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$223.00 ➝ $196.00	+17.58%
4/23/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$260.00 ➝ $230.00	+54.58%
12/19/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$230.00	+16.03%
12/7/2023	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$237.00	+30.22%
4/11/2023	Bank Of America (Bofa) Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$180.00 ➝ $200.00	+16.74%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 07:19 PM ET.

Should I Buy Zoetis Stock? ZTS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, December 17, 2024. Please send any questions or comments about these Zoetis pros and cons to contact@marketbeat.com.

Zoetis
Bull Case

Here are some ways that investors could benefit from investing in Zoetis Inc.:

Zoetis Inc. has shown strong financial performance, reporting a quarterly revenue of $2.40 billion, which exceeded analysts' expectations of $2.29 billion. This indicates robust demand for its products and effective management.
The company recently achieved earnings per share of $1.58, surpassing the consensus estimate of $1.46 by $0.12. This positive earnings surprise can enhance investor confidence and potentially lead to stock price appreciation.
As of the latest trading session, Zoetis Inc. shares are priced at $176.46, reflecting a solid market position and investor interest, which could be attractive for potential buyers looking for growth opportunities.
Institutional investors hold a significant 92.80% of Zoetis Inc.'s stock, suggesting strong confidence from large financial entities in the company's future performance and stability.
Recent analyst ratings have been favorable, with multiple firms assigning "buy" or "strong buy" ratings, indicating a positive outlook for the stock's performance in the near term.

Zoetis
Bear Case

Investors should be bearish about investing in Zoetis Inc. for these reasons:

The stock has a relatively high price-to-earnings (P/E) ratio of 33.17, which may suggest that it is overvalued compared to its earnings. This could deter value-focused investors.
Despite recent growth, the company has a debt-to-equity ratio of 1.26, indicating that it has taken on a significant amount of debt relative to its equity. This could pose risks if the company faces financial challenges.
Zoetis Inc. has experienced fluctuations in its stock price, with a 12-month high of $201.92 and a low of $144.80, which may indicate volatility that could concern risk-averse investors.
Recent market conditions and economic uncertainties could impact the overall performance of the stock, making it a less attractive option for conservative investors.
While the company has strong institutional backing, the high concentration of ownership could lead to less liquidity in the stock, making it harder for individual investors to buy or sell shares without affecting the price.

ZTS Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Zoetis is $215.22, with a high forecast of $230.00 and a low forecast of $196.00.
: 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last twelve months. There is currently 1 hold rating, 8 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZTS shares.
: According to analysts, Zoetis's stock has a predicted upside of 30.56% based on their 12-month stock forecasts.
: Over the previous 90 days, Zoetis's stock had 1 upgrade by analysts.
: Zoetis has been rated by research analysts at JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, and UBS Group in the past 90 days.
: Analysts like Zoetis more than other "medical" companies. The consensus rating for Zoetis is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ZTS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

DeFi Coin on Verge of Breakout! (Ad)

The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years.

Claim your FREE book now before it's too late!

This page (NYSE:ZTS) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zoetis (ZTS) Stock Forecast & Price Target